NAGE
Niagen Bioscience, Inc. Common StockNAGE
NAGE
About: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Employees: 104
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,185% more call options, than puts
Call options by funds: $1.89M | Put options by funds: $147K
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
48% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 33
44% more capital invested
Capital invested by funds: $119M [Q4 2024] → $172M (+$52.7M) [Q1 2025]
13% more funds holding
Funds holding: 123 [Q4 2024] → 139 (+16) [Q1 2025]
2.58% more ownership
Funds ownership: 29.44% [Q4 2024] → 32.02% (+2.58%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
19%
downside
Avg. target
$16.67
22%
upside
High target
$23
69%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Susan Anderson | 17%upside $16 | Buy Maintained | 10 Jun 2025 |
Roth Capital Sean McGowan | 69%upside $23 | Buy Maintained | 6 Jun 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 19%downside $11 | Buy Reiterated | 8 Apr 2025 |
Financial journalist opinion
Based on 4 articles about NAGE published over the past 30 days
Neutral
Business Wire
4 days ago
Niagen Bioscience to Participate in the BIO 2025 International Convention
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event, c.
Positive
Seeking Alpha
4 days ago
Niagen Bioscience: High Conviction, High Expectations
Niagen Bioscience's stock price is breaking out with strong fundamentals, proprietary IP, and a leadership position in the NAD+ longevity market. Revenue and margins are rising, driven by Tru Niagen e-commerce and pharma-grade injectables, with operating leverage and efficient marketing boosting profitability. Valuation is rich, reflecting high expectations for continued growth and clinical pipeline success, but execution risk is elevated at these multiples.
Neutral
Business Wire
6 days ago
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chib.
Neutral
Business Wire
1 week ago
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #InvestorRelations--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference. Mr. Fried is scheduled to participate in a fireside chat on Monday, Jun 9, from 2:15 p.m. to 2:50 p.
Neutral
Seeking Alpha
1 month ago
Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript
Niagen Bioscience, Inc. Q1 2025 - Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Wesley Yu - VP of Finance Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific & Regulatory Affairs Conference Call Participants Ram Selvaraju - H. C. Wainwright Mitch Pinheiro - Sturdivant & Company Sean McGowan - ROTH Capital Partners Matt Dain - Tieton Capital Management Susan Anderson - Canaccord Genuity JP Mark - Farmhouse Equity Research Operator Ladies and gentlemen, thank you for standing by, and welcome to Niagen Biosciences Inc. First Quarter of 2025 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.01 per share a year ago.
Neutral
Business Wire
1 month ago
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%, up 270 basis poin.
Neutral
Business Wire
1 month ago
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the continued expansion of its clinical footprint with additional new clinics now offering pharmaceutical-grade Niagen® IV and injections featuring patented nicotinamide riboside. These new providers join a growing network of almost 600 clinics nationwide offering the first-.
Neutral
Business Wire
1 month ago
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB). Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of.
Neutral
Business Wire
1 month ago
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours o.
Charts implemented using Lightweight Charts™